Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01957748 · ClinicalTrials.gov registry record · NA
CCTG 594: Engagement and Retention in Care for HIV+
A NA study of HIV Positive and Patient Adherence, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 117
- Enrollment target
- 3
- Study locations
NCT01957748: Completed NA study of HIV Positive and Patient Adherence, sponsored by University of California, San Diego.
NCT01957748 is a NA study of HIV Positive and Patient Adherence that has completed, run by University of California, San Diego. The registered enrollment target is 117 participants, below the 636-participant average among 3 other HIV Positive trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01957748, a NA study of HIV Positive and Patient Adherence, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
- 3
- Study locations
Study Summary
CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention in care and maintenance of ART as compared to the current standard of care (SoC) in HIV primary care clinics.
Primary Outcome
The CCTG 594 primary outcome is "time to lost to follow up." Lost to follow up is defined as "no visit with a prescribing HIV provider in the last 180 days. All randomized subjects will be followed for a minimum of 48 weeks. Subjects that do not meet the primary endpoint by the time the study ends will be censored.
Conditions Studied
Interventions
- BEHAVIORAL SoC + ALERT Intervention
Study Locations (3)
California
- University Southern California - Los Angeles
- University of California, San Diego - San Diego
- Harbor-UCLA Medical Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2013-10-08 |
| Est. Completion | 2020-11-24 |
| Phase | NA |
What the finished NCT01957748 record still lists
NCT01957748 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 636-participant average among 3 other HIV Positive trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with HIV Positive appearing as the primary indexed condition, and to 1 intervention - of which SoC + ALERT Intervention is the first listed.
NCT01957748 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01957748 about?
NCT01957748 is a clinical study titled "CCTG 594: Engagement and Retention in Care for HIV+". CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention in care and maintenance of ART as compared to the current standard of care (SoC) in HIV primary care clinics.
What is the current status of trial NCT01957748?
This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2013-10-08. Estimated completion is 2020-11-24.
What conditions does trial NCT01957748 study?
This clinical trial studies the following conditions: HIV Positive, Patient Adherence.
What interventions are being tested in trial NCT01957748?
The interventions under investigation include: SoC + ALERT Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01957748?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01957748 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI